Insight Molecular Diagnostics Inc.
IMDXNasdaqHealthcare · In Vitro & In Vivo Diagnostic Substances · CA · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | $1.9M | $1.5M | $958,000 | $2.2M | $16,000 |
| Operating income | −$51.1M | −$61.0M | −$25.1M | −$18.0M | −$53.7M | −$8.4M |
| Net income | −$50.2M | −$60.7M | −$27.8M | −$72.9M | −$64.1M | −$7.7M |
| Total assets | $25.8M | $35.1M | $74.9M | $100.1M | $159.6M | $55.4M |
| Total liabilities | $57.2M | $47.4M | $49.3M | $60.5M | $94.3M | $21.9M |
| Equity | −$31.5M | −$12.3M | $20.5M | $34.3M | $65.2M | $33.5M |
| EPS (diluted) | $-1.65 | $-4.66 | $-3.75 | $-13.25 | $-0.72 | — |
| Shares out. | 28.6M | 8.3M | 119.3M | 92.2M | 88.9M | 62.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1260.8%
- Net margin
- −1238.5%
- Return on equity
- 159.6%
- Return on assets
- −195.0%
- Return on capital (ROCE)
- −373.7%
- Liabilities / assets
- 222.2%
- Debt / equity
- —
- Book value / share
- $-1.10
- Revenue growth (YoY)
- 115.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -63.82distress
- Accruals / assets
- −108.9%clean
- Beneish M-Score
- -7.77normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 3, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Broadwood Partners, L.P.Activist (13D)Apr 27, 2026
- Awm Investment Company, Inc.Passive (13G)May 9, 2025
- Bio-Rad Laboratories, Inc.Passive (13G)Mar 4, 2025
- Smith Patrick WPassive (13G)Dec 27, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.2M | 2.1 | +65.9% |
| Apr 30, 2026 | 713,244 | 1.9 | +56.5% |
| Apr 15, 2026 | 455,873 | 1.2 | +23.8% |
| Mar 31, 2026 | 368,283 | 1.3 | +99.4% |
| Mar 13, 2026 | 184,700 | 2.1 | -5.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 13, 2026
- Other material eventApr 30, 2026
- Results of operationsMar 26, 2026
- Entered a material agreementFeb 26, 2026
- Entered a material agreement · Other material eventFeb 12, 2026
- Regulation FD disclosureFeb 11, 2026
- Results of operationsNov 10, 2025
- Director / officer changeOct 2, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Corporate family
Spun off from BioTimeLCTX · Dec 31, 2015
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.